as 05-30-2025 3:36pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 2.9B | IPO Year: | 2007 |
Target Price: | $16.22 | AVG Volume (30 days): | 5.3M |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.10 | EPS Growth: | N/A |
52 Week Low/High: | $5.81 - $12.65 | Next Earning Date: | 05-01-2025 |
Revenue: | $543,141,000 | Revenue Growth: | 28.25% |
Revenue Growth (this year): | 19.85% | Revenue Growth (next year): | 23.50% |
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Simply Wall St.
11 days ago
Insider Monkey
19 days ago
GlobeNewswire
25 days ago
Simply Wall St.
a month ago
Zacks
a month ago
MT Newswires
a month ago
Pharmaceutical Technology
a month ago
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.